{"groups":[{"description":"Participants received 1 mg/kg E-602 monotherapy administered weekly via IV infusion.","id":"FG000","title":"E-602 1 mg/kg"},{"description":"Participants received 3 mg/kg E-602 monotherapy administered weekly via IV infusion.","id":"FG001","title":"E-602 3 mg/kg"},{"description":"Participants received 10 mg/kg E-602 monotherapy administered weekly via IV infusion.","id":"FG002","title":"E-602 10 mg/kg"},{"description":"Participants received 20 mg/kg E-602 monotherapy administered weekly via IV infusion.","id":"FG003","title":"E-602 20 mg/kg"},{"description":"Participants received 30 mg/kg E-602 monotherapy administered weekly via IV infusion.","id":"FG004","title":"E-602 30 mg/kg"},{"description":"Participants received 20 mg/kg E-602 monotherapy administered weekly via IV infusion. They also received 350 mg cemiplimab administered every 3 weeks via IV infusion.","id":"FG005","title":"E-602 20 mg/kg in Combination With Cemiplimab"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"9"},{"groupId":"FG003","numSubjects":"15"},{"groupId":"FG004","numSubjects":"15"},{"groupId":"FG005","numSubjects":"21"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"9"},{"groupId":"FG003","numSubjects":"15"},{"groupId":"FG004","numSubjects":"15"},{"groupId":"FG005","numSubjects":"21"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}